Terence W Friedlander

13PUBLICATIONS
114CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersPacific Peoples theory of change models for healthCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.

Matthew D Galsky, Karen A Autio, Christopher R Cabanski

|Jan 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.

Hewitt Chang, Jaqueline Marquez, Brandon K Chen

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Aug 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

Alexandra Drakaki, Thomas Powles, Aristotelis Bamias

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

|Jun 01, 2023
Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study.

Elizabeth Y Wang, Hala T Borno, Samuel L Washington Iii

Pageof 3

Frequent Collaborators

3 joint publications

Lawrence Fong

3 joint publications

Matthew I Milowsky

3 joint publications

Christopher J Hoimes

3 joint publications

Daniel P Petrylak